We will discuss the current FDA-approved first-line NCCN Category 1 treatment options for relapsed or stage IV clear cell RCC, specifically evaluating the various immunotherapy (IO) combination therapies, their clinical application, and considerations for choosing between available combinations. We will also review the side effect/toxicity profile and management strategies for each therapy.
SPEAKERS
Laura Graham is an assistant professor of genitourinary medical oncology at the University of Colorado. Dr. Laura Graham graduated with AOA honors from Rush medical college in Chicago, Illinois. She completed internal medicine residency and hematology/oncology fellowship at the University of Washington in Seattle, WA and served as chief fellow. She is interested in translational and clinical research in patients with genitourinary cancers, with a particular focus on biomarker development and novel therapeutics.
Hiba Ahmad is a board certified clinical oncology pharmacist. She earned PharmD from Creighton University. She completed her PGY-1 residency from Mayo Clinic and her PGY-2 oncology residency from Yale New Haven Hospital. Her interest in solid tumors led to her specialization in breast and gynecologic cancers at Yale for several years. She recently relocated to Colorado and provides outpatient clinical pharmacy services at the University of Colorado with a focus on genitourinary oncology.
Kate Taucher, PharmD, MHA, BCOP, FASHP is the System Manager for Oncology and Infusion Pharmacy Services with UCHealth. She is also the PGY2 Oncology Residency Program Director for UCHealth Memorial Hospital.
She graduated from Virginia Tech in 2007 and received her Doctor of Pharmacy from the University of Maryland School of Pharmacy in 2011. She completed a PGY1 Pharmacy Practice Residency and PGY2 Oncology Residency, both at The Johns Hopkins Hospital in Baltimore, MD. Finally, she completed her Masters in Health Care Administration with a specialization in Health Care Leadership through Capella University in 2017.